The headline reads as positive (92% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › OMCL
Omnicell, Inc. (OMCL) stock analysis
SKIP 8% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Omnicell, Inc. (OMCL) SKIP with 8% confidence at a price of $36.88. That means the signals cancel out; the model sees no clear edge either way.
Analysed price$36.88
Technical picture
The 14-day RSI is 56, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above its 50-day moving average but still below the 200-day: a short-term recovery inside a longer-term downtrend.
Volume is 1.6x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure: bearish structure intact, no fresh break.
The most recent swing high is $46.89 and the swing low is $31.75; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 15.40, which looks expensive relative to its growth.
The company reports a profit margin of 3.1% and revenue growth of +7.5%.
In its latest quarter it earned $0.58 per share, which beat the $0.42 analysts expected, with revenue +7.4% year over year.
Wall Street's average rating is 1.4 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $57.86.
Research notes
OMCL’s bull case is improving profitability: Q3 adjusted EPS of $0.58 beat the $0.42 consensus, while management raised 2026 adjusted EBITDA guidance to $187–$193 million and EPS guidance to $2.48–$2.56. The bear case is sluggish growth—Q3 revenue was essentially flat year over year, and Q4 revenue guidance of $295–$301 million came in below expectations—alongside measured hospital purchasing cycles and intensified competition from BD’s AI-enabled Pyxis platform. The major recent catalyst was the October 29 earnings report, which delivered an earnings beat and higher full-year profit outlook, though the stock remained well below its 52-week high near $55. Analysts’ average price target is about $57.86, implying substantial upside if Omnicell sustains margins and successfully launches Titan XT and OmniSphere.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.08 (SKIP). Technicals: RSI 55.86, MACD bullish, price above SMA50. Fundamentals: PEG 15.40, margin 3.1%, revenue growth 7.5%. Financial results: YoY revenue +7.4%, last EPS surprise +38.1%. Smart Money Concepts: bearish structure intact, no fresh break. FinGPT news read: neutral. Internet research: OMCL’s **bull case** is improving profitability: Q3 adjusted EPS of $0.58 beat the $0.42 consensus, while management raised 2026 adjusted EBITDA guidance to $187–$193 million and EPS guidance to $2.48–$2.56. The **bear case** is sluggish growth—Q3 revenue was essentially flat year over year, and Q4 revenue guidance of $295–$301 million came in below expectations—alongside measured hospital purchasing cycles and intensified competition from BD’s AI-enabled Pyxis platform. The major recent catalyst was the October 29 earnings report, which delivered an earnings beat and higher full-year profit outlook, though the stock remained well below its 52-week high near $55. Analysts’ average price target is about $57.86, implying substantial upside if Omnicell sustains margins and successfully launches Titan XT and OmniSphere. Reference price $36.88; no trade levels (SKIP).
Past ratings for OMCL
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | SKIP | 8% | $36.88 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on OMCL
Oct 29, 2026 · Omnicell's Margin-Driven Beat And Third Profit Raise Mask A Top Line Still Waiting On Titan XT
- Oct 29, 2026: Omnicell's Margin-Driven Beat And Third Profit Raise Mask A Top Line Still Waiting On Titan XT (Earnings Whispers)
- Oct 29, 2026: Omnicell, Inc. Reports Third Quarter 2026 Financial Results and Updates Full Year Guidance (Nasdaq)
- Oct 29, 2026: Omnicell Announces Third Quarter 2026 Financial Results (Business Wire)
- Oct 29, 2026: Omnicell: Q3 Earnings Snapshot (Associated Press)
Frequently asked questions
Is OMCL a buy right now?
As of Oct 29, 2026, our automated model rates Omnicell, Inc. (OMCL) SKIP with 8% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.